Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of ...

Administering medications through the nose as an alternative to injections or IVs is becoming increasingly popular in emergency departments and ambulances, according to a paper by Loyola Medicine ...

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared ...

A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in ...

The combination of intranasal insulin (INI) and the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin had positive effects on cognition and immune and inflammatory biomarkers in patients ...

Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.

ANAHEIM, Calif.—Bremelanotide, an investigational medication administered into the nose, may improve sexual satisfaction and self-esteem in men with erectile dysfunction (ED), according to a new study ...

When it comes to migraine treatments, one-size-fits-all does not apply. Fortunately, a new option is on the horizon. Atzumi — a dihydroergotamine (DHE) nasal powder — received approval from the U.S.

The Food and Drug Administration on Thursday approved a new nasal spray to treat migraines. The spray will be available in July and is designed to treat migraines in 15 minutes. Pfizer acquired the ...

Allergy medications that cause drowsiness are best taken at night, while non-drowsy options can be taken in the morning or ...